MET409, an Optimized Sustained FXR Agonist, Was Safe and Well-Tolerated in a 14-Day Phase 1 Study in Healthy Subjects

Back
Poster presentation at EASL – The International Liver Congress, April 2019

EASL 2019 MET409

Download PDF